Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia. Interferon alfa-2b has been used for decades to treat PV but r...
Ropeginterferon alfa-2b is indicated for the treatment of adult patients with polycythemia vera.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.